NCI-Funded Device Start-Ups Offer Game-Changing Technologies
At the NCI SBIR 2012 Investor Forum, a select group of SBIR grant-funded emerging cancer device companies presented promising next-generation technologies poised to dramatically impact survival from a variety of cancers, including deadly lung, liver, and esophageal malignancies.
You may also be interested in...
'Not-Approvable' Letter Fits Trend For Optical Cancer Detectors, Guided Therapeutics Says
The company's response to an FDA not-approvable letter for its LuViva cervical cancer scanner will be guided by the experiences of other light-based cancer detector developers that encountered the same initial setback. The firm's likely next step: petitioning FDA for an advisory panel meeting.
A Bright Future For Optical Imaging
One bright spot emerging in this otherwise lackluster economy is the market for optical imaging technologies. Optical imaging encompasses a wide array of current and emerging techniques that use light as the primary imaging modality to characterize local anatomy down to cellular and molecular levels.
Can E6E7 Alter The Competitive Balance In The Crowded HPV Test Market?
The October introduction of Gen-Probe’s new cervical cancer screening test may up the stakes in the battle over market share in testing for HPV, the cause of cervical cancer. That’s good news for several companies. One is OncoHealth, which is developing a low-cost protein-based test for direct measurement of E6E7, two important oncoproteins associated with HPV progression to cancer that are a part of Gen-Probe’s new test panel.